SOAT1 and acute lymphoblastic leukemia: A randomized controlled trial (RCT) is currently recruiting patients with newly diagnosed pediatric ALL, including T-ALL, and they will be treated with conventional combined chemotherapy and ruxolitinib for those patients with JAK/STAT pathway aberration.